Deals of the Week Looks at Ultra-Orphan Drug Pricing
Executive Summary
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.